Preclinical data for ALG.APV-527, a new immunotherapeutic candidate for the treatment of a variety of 5T4-positive solid tumors, being presented at the 33rd annual meeting of the Society for Immunotherapy of Cancer’s (SITC) held in Washington, D.C., November 9-11, 2018, confirms that the investigational agent selectively activates and enhances tumor-directed T-cell and Natural Killer (NK) cell responses.

The investigational agent ALG.APV-527 is a bispecific antibody (4-1BB x 5T4) intended for tumor-directed treatment of solid cancers. The drug is jointly developed by Alligator Bioscience and Aptevo Therapeutics and was built using Aptevo’s ADAPTIR? bispecific platform and combines binding domains sourced from the ALLIGATOR-GOLD? human scFV library.

The agent consists of two parts, one part activating tumor-specific T cells through the co-stimulatory receptor 4-1BB (CD137), which is present on activated cytotoxic T cells and natural killer (NK) cells; the other part binding to the 5T4 protein dispayed on the surface of tumor cells. This enables the immune-activating effect of ALG.APV-527 to be directed specifically to the tumor

Once activated, the drug is designed to promote potent and selective tumor-directed immune activation in the presence of 5T4 antigen-expressing tumor cells, which are present on many different types of solid tumors and not against normal tissue.

Preclinical Data
The preclinical data show that ALG.APV-527 localizes to 5T4 positive tumors and selectively stimulates and enhances tumor-directed T cell and NK cell responses, displaying potent anti-tumor effects. Notably, the preclinical in vitro data demonstrated that in the presence of 5T4-positive cells increases CD8+ cytotoxic T cells’ ability to secrete the pro-inflammatory cytokine IFN-gamma production, but only in the presence of human tumor cells that display 5T4 at their surface, while at the same time enhancing the cytotoxic profile of NK cells

Advertisement #3

Range of tumors
Additionally, these new data confirm that 5T4 antigen is present on a wide range of tumor types. 5T4-positive tumor cells were detected in tumor samples from non-small cell lung cancer (NSCLC) , head and neck, mesothelioma-, pancreatic-, bladder-, renal- and ovarian cancer, but not in normal tissues such as liver or heart.

“The latest preclinical data further strengthen ALG.APV-527’s potential to localize to 5T4-expressing tumors, where it selectively can activate the immune system and enhance tumor specific T cell or NK activation at the tumor site, potentially providing a favorable safety profile while enhancing efficacy,” said Christina Furebring, Ph.D., Senior Vice President Research at Alligator.

“We are currently compiling a preclinical package with the goal of submitting a clinical trial application (CTA) in late 2019,” she added.

“Our novel bispecific candidate, ALG.APV-527, continues to show promising results in preclinical in vitro and in vivo studies. Featuring target-driven T cell activation, optimized stability, an antibody-like serum half-life of 9 days, and good manufacturing properties,” explained Jane Gross, Ph.D., Chief Scientific Officer for Aptevo.

Aptevo and Alligator believe that ALG.APV-527 has the potential to be a unique anti-cancer therapeutic for the treatment of numerous 5T4-expressing solid tumors with high unmet medical need. We look forward to filing the CTA next year and commencing clinical study of this promising immunotherapy,” she added.

Potent Tumor-Directed T Cell Activation and Tumor Inhibition Induced by a 4-1BB x 5T4 ADAPTIR? Bispecific Antibody. Presented on November 9, 2018 from 12:45pm ? 2:45 pm and 6:30 pm ? 8:30 pm ET.

Last Editorial Review: November 9, 2018

Featured Image: The Moon is seen as is rises, Sunday, Dec. 3, 2017 in Washington. Today’s full Moon is the first of three consecutive supermoons. The two will occur on Jan. 1 and Jan. 31, 2018. A supermoon occurs when the moon?s orbit is closest (perigee) to Earth at the same time it is full.? Courtesy: ? 2018 NASA/Bill Ingalls. Used with permission.

Copyright ? 2010 ? 2018 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco?Zine, Oncozine and The Onco?Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.

Advertisement #5